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Case ReportLong-Term Disease-Free Survival in a Young
Patient With Hormone ReceptorePositive Breast
Cancer and Oligometastatic Disease in the Brain
Poornima Saha, Andrea L. Amico, Olufunmilayo I. OlopadeClinical Practice Points
 The incidence of brain metastases in breast cancer
varies by subtype.
 Various treatment options exist for the management of
brain metastases in breast cancer.
 Long-termdisease-free survival is possible, as seen in this
case of a young woman with hormone receptorepositive
breast cancer and oligometastatic brain metastasis.Clinical Breast Cancer, Vol. 16, No. 3, e61-3 ª 2016 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Breast cancer is second only to lung cancer as the leading cause of
cancer brain metastasis. Brain metastasis usually occurs late in the
natural history of breast cancer and often in the presence of
extensive extracranial metastasis.1 The central nervous system
(CNS) presents as the sole site of metastatic disease in approximately
17% of patients according to a recent Austrian study.2 We present a
case of a young, premenopausal woman with estrogen receptor
(ER)epositive breast cancer with brain-only metastatic disease who
has been treated with ovarian suppression, anastrozole, whole brain
radiation therapy (WBRT), surgical resection, and intracavitary
chemotherapy and continues to do well 13 years after her initial
diagnosis.
Case Report
Our patient with a family history of breast cancer was diagnosed
with breast cancer in 2002 at age 21 years, after presenting with
bloody right nipple discharge. She underwent right breast lumpec-
tomy, and pathology showed low-grade ductal carcinoma in situ
(DCIS) with a microscopic focus of invasive ductal carcinoma that
measured <2 mm. Margins were positive for DCIS. One month
later, she underwent a right simple mastectomy and left prophylacticDepartment of Medicine, The University of Chicago, Chicago IL
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foci of low-grade DCIS in the right breast, and margins were free of
tumor. The left breast was pathologically unremarkable. There is no
information available about hormone receptor or HER2 status from
that time.
In 2003, she presented with a tender right axillary mass. Ultra-
sound revealed a 1.5-cm lymph node, and needle aspiration revealed
metastatic carcinoma. She underwent right axillary lymph node
dissection, and 8 of 13 lymph nodes were positive for invasive ductal
carcinoma, which was strongly ER positive, progesterone receptor
negative, and HER2 negative. Metastatic evaluation was negative for
distant metastatic disease.
She received 4 cycles of adjuvant dose-dense Adriamycin and
Cytoxan, followed by 4 cycles of Taxol. This was followed by
adjuvant radiation to the right chest wall, axilla, supraclavicular
fossa, and internal mammary lymph nodes. She then began ovarian
suppression with leuprolide and antiestrogen therapy with
anastrozole.
In 2004, she presented with nausea, vomiting, and headaches.
Magnetic resonance imaging (MRI) of her brain revealed a cere-
bellar and frontal lobe lesion with radiographic appearance of me-
tastases. She underwent craniotomy and resection of the cerebellar
lesion, followed by WBRT. Pathology conﬁrmed the diagnosis of
metastatic adenocarcinoma consistent with her breast primary.
Testing for ER, progesterone receptor, and HER2 expression was
not done. One month after completion of WBRT, she underwent
stereotactic radiosurgery (SRS) to the frontal lobe lesion.
In 2005, she was hospitalized for new-onset seizures. MRI of the
brain revealed a new ring-enhancing metastatic lesion in the frontalBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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frontal lobe lesion. Later that year, a follow-up brain MRI revealed
a new, asymptomatic right parietal lesion, which was also surgically
resected. Pathology was consistent with metastatic invasive ductal
carcinoma. Given her young age, she underwent germline BRCA
sequencing, which revealed a BRCA2 polymorphism with no dele-
terious mutation detected in the BRCA1 or BRCA2 genes.
In December 2006, a follow-up brain MRI was concerning for
recurrence in the region of the initial right parietal lobe lesion, and
she underwent craniotomy in January 2007 for resection followed
by intracavitary carmustine wafer (Gliadel) placement. Serial brain
MRI studies between February 2007 and April 2015 showed no
evidence of recurrence, and body computed tomography imaging
showed no evidence of extracranial metastasis.
She continued taking anastrozole and leuprolide from November
2002 to April 2014, at which point she discontinued therapy to
become pregnant. She is currently 31 years old—13 years from her
initial diagnosis—and has had no lasting neurologic deﬁcits and no
more seizures. She continues to work and live an active lifestyle.
Discussion
An estimated 10% to 30% of all patients with breast cancer
eventually will develop brain metastases.3 The incidence of brain
metastases in breast cancer is increasing because of the aging pop-
ulation, detection of subclinical disease, and better control of sys-
temic disease. Breast cancer brain metastases are associated with
signiﬁcant morbidity and mortality, with the shortest survival time
compared with other sites of metastatic spread.4
In patients with early-stage breast cancer, the cumulative inci-
dence rates of brain metastasis are highest in those with HER2-
positive and triple-negative breast cancer (TNBC) and lowest in
ER-positive disease.4,5 Several studies have shown that the outcomes
in patients with breast cancer brain metastases also differ by tumor
subtype. In a study of 205 patients with breast cancer and brain
metastases (28% TNBC, 53% HER2 positive, 19% luminal type),
the median survival from the onset of brain metastasis was 3.7
months for TNBC, 9 months for HER2 positive, and 15 months
for luminal type breast cancer. Median survival from brain metas-
tases was improved in all subgroups with systemic treatment after
WBRT, but was particularly improved in the luminal subgroup
with an improvement in median survival from 3 to 14 months with
systemic therapy.6
Another study of 140 patients with breast cancer and brain
metastases found that 27 patients (19%) were alive at least 36
months after diagnosis of brain metastases, and 10 patients (7%)
were alive at least 60 months after this diagnosis. Of these 27 pa-
tients with signiﬁcant long-term disease-free survival, 77% had ER-
positive disease, 70% had progesterone receptorepositive disease,
44% had Her2-positive disease, and 74% had a solitary brain
lesion.7
Brain Only Metastatic Breast
Cancer
This case suggests that the pathobiology of patients with brain
only disease may be inherently different with distinct clinical out-
comes. In 2012, Berghoff et al1 evaluated a cohort of 222 patients
with breast cancer and brain metastases (26% luminal, 47% Her2,Clinical Breast Cancer June 201627% triple negative) at their institution. Of these, 38 patients
(17%) had brain-only metastatic breast cancer (BO-MBC). The
patients with BO-MBC had signiﬁcantly longer median overall
survival compared with patients with extracranial metastases (11 vs.
6 months). Long-term survival of >3 years also was signiﬁcantly
more common in patients with brain only metastases (seen in 7/38
patients, 18%). Of note, no association with BO-MBC and breast
cancer subtype was seen in this study.2
Treatment of Brain Metastasis in
Breast Cancer
Favorable prognostic factors for BO-MBC include Karnofsky
performance status >70%, younger age, fewer lesions (<5 in some
studies, but no consensus on this), and ER expression.2,8 WBRT
remains a current standard of care.9 SRS is another option for pa-
tients with solitary or oligometastatic CNS disease and has a local
control rate of up to 90%.9
WBRT and SRS have been used together with improved disease
control rates and reduced local recurrence rates compared with SRS
alone. However, the combination is associated with signiﬁcantly
more neurocognitive morbidity than SRS alone.9,10 A recent study
suggested that for patients aged less than 50 years, there may be a
survival advantage for SRS alone, compared with WBRT, and
studies are ongoing to determine whether use of WBRT should be
reserved for patients who have multiple brain metastases that are not
amenable to SRS or resection.11 When possible, SRS or neurosur-
gical resection should be considered.
Past studies12 have shown that repeat neurosurgical resection in
select patients can result in neurologic improvement with minimal
morbidity and mortality, as we reported. Local recurrence after
resection can occur in up to 46% of cases.13 WBRT can be used in the
adjuvant setting and has been shown to reduce local recurrence and
improve disease control elsewhere in the brain.11 No overall survival
beneﬁt has been demonstrated with the use of adjuvant WBRT, so a
thorough discussion of the risks and beneﬁts is warranted.
More recently, investigators have considered the use of carmus-
tine wafer placement for salvage treatment of brain metastases (not
limited to breast cancer) that have recurred despite SRS or surgical
resection. These wafers, under the brand name Gliadel, were
approved by the Food and Drug Administration in 1996 for the
treatment of malignant glioma, and more recent studies have eval-
uated their adjuvant use in the setting of secondary CNS malig-
nancies. The wafers deliver a high concentration of chemotherapy
(carmustine/BCNU) locally, after being surgically placed at the site
of disease recurrence. Early clinical and preclinical studies have
supported the safety and tolerability of this therapy for patients with
brain metastases, and recent studies demonstrated that successful
local control can be achieved in patients with brain metastasis from
breast cancer, nonesmall cell and small cell lung cancer, gastroin-
testinal cancers, thyroid cancer, and melanoma.13,14
Conclusions
We present the case of a young, premenopausal woman with
ER-positive metastatic breast cancer to the brain who has had
prolonged progression-free disease survival after aggressive treat-
ment to achieve local control and hormone suppression. After
multiple successful local treatment modalities including SRS,
Poornima Saha et alWBRT, neurosurgery, and carmustine wafers, she has no evidence
of signiﬁcant neurocognitive dysfunction. In the absence of
consensus guidelines for the management of brain-only oligome-
tastatic breast cancer, we emphasize the importance of a multi-
disciplinary and multimodality approach. A patient with a good
performance status, absent or well-controlled extracranial disease, and
few metastatic lesions in the brain should ﬁrst consider aggressive local
therapy with surgery or SRS. Adjuvant WBRT can be considered,
but, when used in conjunction with SRS, the risk of neurocognitive
morbidity should be discussed. Use of carmustine wafers should be
considered as a salvage option in patients with good performance
status and stable systemic disease who have had disease progression
after surgery or SRS.References
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